CN112279917B - Monoclonal antibody of mouse anti-cell surface glycoprotein CD138 capable of being applied to tumor cell capture - Google Patents

Monoclonal antibody of mouse anti-cell surface glycoprotein CD138 capable of being applied to tumor cell capture Download PDF

Info

Publication number
CN112279917B
CN112279917B CN202010484563.8A CN202010484563A CN112279917B CN 112279917 B CN112279917 B CN 112279917B CN 202010484563 A CN202010484563 A CN 202010484563A CN 112279917 B CN112279917 B CN 112279917B
Authority
CN
China
Prior art keywords
antibody
monoclonal antibody
surface glycoprotein
cell
cell surface
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202010484563.8A
Other languages
Chinese (zh)
Other versions
CN112279917A (en
Inventor
孟逊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Puzhong Discovery Pharmaceutical Technology Shanghai Co ltd
Original Assignee
Puzhong Discovery Pharmaceutical Technology Shanghai Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Puzhong Discovery Pharmaceutical Technology Shanghai Co ltd filed Critical Puzhong Discovery Pharmaceutical Technology Shanghai Co ltd
Priority to CN202010484563.8A priority Critical patent/CN112279917B/en
Publication of CN112279917A publication Critical patent/CN112279917A/en
Application granted granted Critical
Publication of CN112279917B publication Critical patent/CN112279917B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The invention relates to a monoclonal antibody, in particular to a monoclonal antibody of a mouse anti-cell surface glycoprotein CD138, which can be applied to capturing tumor cells, and comprises the following steps: s1, protein QC; s2, animal immunization; s3, serum detection and screening; s4, fusion and screening; s5, subcloning and screening; s6, preparing an antibody supernatant; s7, antibody verification. The monoclonal antibody of the mouse anti-cell surface glycoprotein CD138, which can be applied to tumor cell capture, has the characteristics of high affinity, high specificity, multiple application scenarios and the like, and can be applied to living cell enrichment.

Description

Monoclonal antibody of mouse anti-cell surface glycoprotein CD138 capable of being applied to tumor cell capture
Technical Field
The invention relates to a monoclonal antibody, in particular to a monoclonal antibody of a mouse anti-cell surface glycoprotein CD138, which can be applied to tumor cell capture.
Background
CD138 is a multimeric proteoglycan, belongs to a member of the adhesion molecule integrin transmembrane-binding proteoglycan family, is mainly distributed on the surfaces of endothelial cells, epithelial cells, fibroblasts and keratinocytes, can be combined with a series of ligands such as cell adhesion molecules, matrix molecules, growth factors, enzyme inhibitors and the like through a heparin sulfate side chain on the molecular surfaces of the members, and can regulate the interaction between cells and microenvironment in a co-receptor mode, thus participating in the regulation of a series of physiological processes such as tissue organ differentiation and development, angiogenesis, tissue regeneration and the like, and being related to proliferation, adhesion and migration of the cells. The soluble CD138 molecule can be used as an antagonist or an agonist of basic fibroblast growth factor in tissue injury repair, participates in the injury repair process, and has the effect of inhibiting tumor cell proliferation. Along with the deep research, the expression of CD138 molecules is found to have important roles in the growth, metastasis and other processes of malignant tumor cells in the air, can be used as an index for judging tumor prognosis, has important significance for knowing clinical diagnosis and immunotherapy, has few antibody products taking CD138 as a target carrier in the market at present, and has no data to indicate that the CD138 molecules can be used for enriching living tumor cells. While there is a lack of effective antibody tools for this research area.
Disclosure of Invention
The invention aims to provide a tool for researching targeted proteins, and the deeper research on protein expression changes and protein network patterns of different cancer patients and different stages of cancers is realized.
The technical scheme adopted by the invention is as follows: a monoclonal antibody of a mouse anti-cell surface glycoprotein CD138 applicable to tumor cell capture, which comprises the following steps:
s1, protein QC: purchasing commercial proteins;
s2, animal immunization: selecting 6 Balb/c mice for antigen immunization, monitoring serum titers of the Balb/c mice to determine optimal immunized mice, performing boosting for 3 to 4 times after primary immunization, detecting titer by taking serum of the mice after boosting, screening out qualified mice with one impact for fusion, and continuing boosting for one to two times until the titer is highest for fusion;
s3, serum detection and screening: immunized mice are subjected to orbital blood collection, and the serum titer is detected by ELISA, so that the qualified serum titer is determined;
s4, fusion and screening: fusing the whole spleen and 1/2 lymph nodes with a myeloma SP2/0 cell line, paving fused cells on 4 384-well plates for culture, collecting supernatants of all the wells, screening immune proteins by ELISA, performing microscopic examination on positive Kong Zhuaidao-well plates with cells for continuous culture, collecting supernatants of all the wells after a few days of growth, detecting reaction with soluble fragment detection antigen by ELISA, further detecting protein binding of different dilutions of positive wells, and performing affinity sequencing on 20 parent clones with highest affinity for each fusion immunogen into subclones;
s5, subcloning and screening: subcloning by limiting dilution method and ELISA screening to obtain monoclonal hybridoma cells, spreading 96-well plates on the cells, culturing to cover the bottom of about 1/6, ELISA detecting the reaction of each well supernatant on immune antigen, taking two wells with high OD value and good cell state to enter the next round of subcloning, repeating the steps until the positive rate of cell strains in the wells is 100%, obtaining monoclonal cell strains at this time, immediately expanding and culturing all positive cells after the last round of subcloning, freezing one part for later use, and preparing the other part of supernatant or ascites;
s6, preparing antibody supernatant: injecting the finally obtained monoclonal cell strain into an F1 mouse through the abdomen for antibody production, purifying the generated ascites by using Protein A/G, and using the ascites for subsequent detection;
s7, antibody verification: ELISA, western blotting, co-immunoprecipitation, mass spectrometry, antibody chip and other verification are performed on the obtained monoclonal antibody cell strain to determine the most effective antibody.
As a preferred technical scheme of the invention: the Balb/c mice in the S2 are 8-12 week old Balb/c mice.
As a preferred technical scheme of the invention: and the serum titer gridlines in the S3 are serum titers of more than 10K.
As a preferred technical scheme of the invention: the fusion process in S4 is optimized PEG fusion.
As a preferred technical scheme of the invention: the number of cells per well on 4 384 well plates in S4 is 10 2 ～10 4 。
As a preferred technical scheme of the invention: the ELISA verification in S7 specifically comprises the following steps: coating an antibody to be detected on a 96-hole ELISA plate, incubating, washing, blocking the skimmed milk overnight, washing with PBS, and preserving at 4 ℃ for later use; then, antigen incubation and PBS washing are carried out, a control is arranged at the same time, his-HRP and TMB are added for color reaction, and the enzyme label instrument reads.
As a preferred technical scheme of the invention: the antibody chip in the S7 is specifically: the anti-CD 138 antibody and the control antibody are spotted on a glass sheet with NC film as a matrix by using a chip spotter to form antibody spots with the diameter of 100um, the whole protein of A375 is subjected to biotin labeling, incubated on an antibody chip according to the concentration of 2ug/ml, incubated for half an hour at room temperature, gently washed three times by PBS, incubated by CY3-SA fluorescent secondary antibody, washed three times by PBS, and the chip is scanned by using a GenePix fluorescent chip scanner with 523 nm.
As a preferred technical scheme of the invention: the monoclonal antibody variable region sequencing result of the mouse anti-cell surface glycoprotein CD138 is as follows:
VHF1
EVKLEESGGGLVQPGGSMELSCVAS
VHCDR1
GFTFSKYW
VHF2
MNWVRQSPEKGLEWVAA
VHCDR2
IRLKSNNYAT
VHF3
HYAESVKGRFTISRDDSKNSVYLQMNNLRTEDTGIYYC
VHCDR3
TATGNFDV
VHF4
WGAGTTVTVSS
VLF1
DIKMTQSPSSMYASLGERVTITCKAS
VLCDR1
QDINSY
VLF2
LSWFQQKPGKSPKTLMY
VLCDR2
RAN
VLF3
RLVDGVPSRFSGSGSGQDYSLTISSLEYEDMGIYYC
VLCDR3
LQYDEFPPT
VLF4
FGGGTKVEIK。
the monoclonal antibody of the mouse anti-cell surface glycoprotein CD138, which can be applied to tumor cell capture, has the characteristics of high affinity, high specificity, multiple application scenarios and the like, and can be applied to living cell enrichment.
Drawings
FIG. 1 is a graph showing the results of antibody flow cytometry in a preferred embodiment of the present invention;
FIG. 2 is a graph showing the killing result of cancer cells according to the preferred embodiment of the present invention;
FIG. 3 is a graph showing the results of an antibody chip test in a preferred embodiment of the present invention.
Detailed Description
It should be noted that, under the condition of no conflict, the embodiments and features in the embodiments may be combined with each other, and the technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are only some embodiments, but not all embodiments of the present invention. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.
Referring to FIG. 1, a preferred embodiment of the present invention provides a monoclonal antibody of the mouse anti-cell surface glycoprotein CD138 for tumor cell capture, which comprises the following steps:
s1, protein QC: purchasing commercial proteins; specifically, the purchase in this embodiment is the goods number of the ACRO company: protein SD 1-H5228.
S2, animal immunization: selecting 6 Balb/c mice for antigen immunization, monitoring serum titers of the Balb/c mice to determine optimal immunized mice, performing boosting for 3 to 4 times after primary immunization, detecting titer by taking serum of the mice after boosting, screening out qualified mice with one impact for fusion, and continuing boosting for one to two times until the titer is highest for fusion; in particular, optimized adjuvants and immunization methods are capable of producing high affinity antibodies (IgG subtypes) against most antigens.
S3, serum detection and screening: immunized mice are subjected to orbital blood collection, and the serum titer is detected by ELISA, so that the qualified serum titer is determined;
s4, fusion and screening: fusing the whole spleen and 1/2 lymph nodes with a myeloma SP2/0 cell line, paving fused cells on 4 384-well plates for culture, collecting supernatants of all the wells, screening immune proteins by ELISA, performing microscopic examination on positive Kong Zhuaidao-well plates with cells for continuous culture, collecting supernatants of all the wells after a few days of growth, detecting reaction with soluble fragment detection antigen by ELISA, further detecting protein binding of different dilutions of positive wells, and performing affinity sequencing on 20 parent clones with highest affinity for each fusion immunogen into subclones;
s5, subcloning and screening: subcloning by limiting dilution method and ELISA screening to obtain monoclonal hybridoma cells, spreading 96-well plates on the cells, culturing to cover the bottom of about 1/6, ELISA detecting the reaction of each well supernatant on immune antigen, taking two wells with high OD value and good cell state to enter the next round of subcloning, repeating the steps until the positive rate of cell strains in the wells is 100%, obtaining monoclonal cell strains at this time, immediately expanding and culturing all positive cells after the last round of subcloning, freezing one part for later use, and preparing the other part of supernatant or ascites;
s6, preparing antibody supernatant: the finally obtained monoclonal cell strain, in this example, 7 monoclonal cell strains were finally obtained, which were injected into F1 mice via the abdomen for antibody production, and the ascites produced was purified with Protein a/G and used for subsequent detection;
s7, antibody verification: ELISA, western blotting, co-immunoprecipitation, mass spectrometry, antibody chip and the like are carried out on the obtained 7 monoclonal antibody cell strains, and the most effective antibody is determined.
In this embodiment: the Balb/c mice in the S2 are 8-12 week old Balb/c mice.
In this embodiment: and the serum titer gridlines in the S3 are serum titers of more than 10K.
In this embodiment: the fusion process in S4 is optimized PEG fusion.
In this embodiment: the number of cells per well on 4 384 well plates in S4 is 10 2 ～10 4 。
In this embodiment: the ELISA verification in S7 specifically comprises the following steps: and (3) coating the antibody to be detected on a 96-well ELISA plate, incubating, washing, blocking with skimmed milk overnight, washing with PBS, and preserving at 4 ℃ for later use. Antigen incubation (gradient dilution), PBS wash, and control were set. His-HRP (antigen with His tag) was added, TMB was developed for reaction, and the microplate reader was read.
In this example, the inventors verified the affinities of the 8 cell lines obtained by ELISA affinity verification of S7 as follows:
nM 100 50 25 12.5 6.25 3.125 1.57 0.78 0.4 0.2 0.1 NC affinity nM
2O5 3.166 3.229 3.243 2.935 2.908 2.730 2.120 1.573 0.886 0.511 0.256 0.055 0.2
2K19 3.900 3.779 3.900 3.900 3.955 3.779 2.746 1.882 1.298 0.511 0.263 0.058 0.2
2B14 2.719 2.538 2.445 2.170 1.593 0.917 0.571 0.236 0.132 0.068 0.057 0.056 1.57
3F3 3.900 3.954 3.887 3.829 3.733 3.778 3.454 3.025 2.171 1.218 0.536 0.076 0.1
1H16-B 3.390 3.286 3.131 2.955 2.716 2.587 2.181 1.948 1.333 0.952 0.509 0.056 0.1
1F5 2.720 2.289 1.972 1.477 1.062 0.714 0.505 0.271 0.163 0.111 0.093 0.068 1.57
1J13 3.900 3.760 3.812 3.673 3.569 3.414 2.929 2.044 1.135 0.615 0.277 0.056 0.2
It should be added that in this example we also performed flow cytometry validation of antibodies and cancer cell killing experiments, respectively.
As shown in fig. 1 in particular, the flow cytometry validation of antibodies was: RPMI-8226 cells were used as the detection cell line, washed with PBS, digested with EDTA, transferred to a centrifuge tube, centrifuged to discard the supernatant, resuspended in PBS, goat serum blocked at room temperature for 1 hour, primary antibody incubation, working concentration 50ug/ml, fluorescent secondary antibody incubation, working concentration 1:300. the results show that the antibody can be applied to flow cytometry.
As shown in fig. 2, the cancer cell killing experiment is: preparing 100ul of cell RPMI-8226 suspension in a 96-well plate, pre-culturing for 24 hours, adding 10ul of anti-CD 138 antibodies with different dilution gradients into a culture plate, adding mouse secondary antibodies coupled with small molecule drugs, culturing for 3 days, adding 10ul of CCK-8 solution into each well, incubating for 1-4 hours, and measuring the absorbance at 450nm by using an enzyme-labeled instrument. Experimental results show that the antibody has good killing effect on cancer cells RPMI-8226.
In this embodiment: the antibody chip in the S7 is specifically: the anti-CD 138 antibody and the control antibody are spotted on a glass sheet with NC film as a matrix by using a chip spotter to form antibody spots with the diameter of 100um, the whole protein of A375 is subjected to biotin labeling, incubated on an antibody chip according to the concentration of 2ug/ml, incubated for half an hour at room temperature, gently washed three times by PBS, incubated by CY3-SA fluorescent secondary antibody, washed three times by PBS, and the chip is scanned by using a GenePix fluorescent chip scanner with 523 nm.
The experimental results are shown in FIG. 3, and the experimental results show that the anti-CD 138 (clone 1H 16-B) has obvious enrichment binding effect on the target protein, the fluorescence intensity is high, and the antigen-antibody binding reaction of the control antibody does not occur.
In this embodiment: the monoclonal antibody variable region sequencing result of the mouse anti-cell surface glycoprotein CD138 is as follows:
VHF1
EVKLEESGGGLVQPGGSMELSCVAS
VHCDR1
GFTFSKYW
VHF2
MNWVRQSPEKGLEWVAA
VHCDR2
IRLKSNNYAT
VHF3
HYAESVKGRFTISRDDSKNSVYLQMNNLRTEDTGIYYC
VHCDR3
TATGNFDV
VHF4
WGAGTTVTVSS
VLF1
DIKMTQSPSSMYASLGERVTITCKAS
VLCDR1
QDINSY
VLF2
LSWFQQKPGKSPKTLMY
VLCDR2
RAN
VLF3
RLVDGVPSRFSGSGSGQDYSLTISSLEYEDMGIYYC
VLCDR3
LQYDEFPPT
VLF4
FGGGTKVEIK。
it will be evident to those skilled in the art that the invention is not limited to the details of the foregoing illustrative embodiments, and that the present invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive, the scope of the invention being indicated by the appended claims rather than by the foregoing description, and all changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein. Any reference sign in a claim should not be construed as limiting the claim concerned.
Furthermore, it should be understood that although the present disclosure describes embodiments, not every embodiment is provided with a separate embodiment, and that this description is provided for clarity only, and that the disclosure is not limited to the embodiments described in detail below, and that the embodiments described in the examples may be combined as appropriate to form other embodiments that will be apparent to those skilled in the art.
Sequence listing
<110> general public discovery of pharmaceutical technology (Shanghai) Limited
<120> monoclonal antibody against cell surface glycoprotein CD138 of mice applicable to tumor cell capturing
<141> 2023-10-10
<160> 14
<170> SIPOSequenceListing 1.0
<210> 1
<211> 25
<212> PRT
<213> Artificial Sequence
<400> 1
Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Met Glu Leu Ser Cys Val Ala Ser
20 25
<210> 2
<211> 8
<212> PRT
<213> Artificial Sequence
<400> 2
Gly Phe Thr Phe Ser Lys Tyr Trp
1 5
<210> 3
<211> 17
<212> PRT
<213> Artificial Sequence
<400> 3
Met Asn Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala
1 5 10 15
Ala
<210> 4
<211> 10
<212> PRT
<213> Artificial Sequence
<400> 4
Ile Arg Leu Lys Ser Asn Asn Tyr Ala Thr
1 5 10
<210> 5
<211> 38
<212> PRT
<213> Artificial Sequence
<400> 5
His Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp
1 5 10 15
Ser Lys Asn Ser Val Tyr Leu Gln Met Asn Asn Leu Arg Thr Glu Asp
20 25 30
Thr Gly Ile Tyr Tyr Cys
35
<210> 6
<211> 8
<212> PRT
<213> Artificial Sequence
<400> 6
Thr Ala Thr Gly Asn Phe Asp Val
1 5
<210> 7
<211> 11
<212> PRT
<213> Artificial Sequence
<400> 7
Trp Gly Ala Gly Thr Thr Val Thr Val Ser Ser
1 5 10
<210> 8
<211> 26
<212> PRT
<213> Artificial Sequence
<400> 8
Asp Ile Lys Met Thr Gln Ser Pro Ser Ser Met Tyr Ala Ser Leu Gly
1 5 10 15
Glu Arg Val Thr Ile Thr Cys Lys Ala Ser
20 25
<210> 9
<211> 6
<212> PRT
<213> Artificial Sequence
<400> 9
Gln Asp Ile Asn Ser Tyr
1 5
<210> 10
<211> 17
<212> PRT
<213> Artificial Sequence
<400> 10
Leu Ser Trp Phe Gln Gln Lys Pro Gly Lys Ser Pro Lys Thr Leu Met
1 5 10 15
Tyr
<210> 11
<211> 3
<212> PRT
<213> Artificial Sequence
<400> 11
Arg Ala Asn
1
<210> 12
<211> 36
<212> PRT
<213> Artificial Sequence
<400> 12
Arg Leu Val Asp Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly
1 5 10 15
Gln Asp Tyr Ser Leu Thr Ile Ser Ser Leu Glu Tyr Glu Asp Met Gly
20 25 30
Ile Tyr Tyr Cys
35
<210> 13
<211> 9
<212> PRT
<213> Artificial Sequence
<400> 13
Leu Gln Tyr Asp Glu Phe Pro Pro Thr
1 5
<210> 14
<211> 10
<212> PRT
<213> Artificial Sequence
<400> 14
Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
1 5 10

Claims (1)

1. A monoclonal antibody against the cell surface glycoprotein CD138 of mice, which is applicable to tumor cell capture, characterized in that the variable region sequencing results are:
VHF1
EVKLEESGGGLVQPGGSMELSCVAS
VHCDR1
GFTFSKYW
VHF2
MNWVRQSPEKGLEWVAA
VHCDR2
IRLKSNNYAT
VHF3
HYAESVKGRFTISRDDSKNSVYLQMNNLRTEDTGIYYC
VHCDR3
TATGNFDV
VHF4
WGAGTTVTVSS
VLF1
DIKMTQSPSSMYASLGERVTITCKAS
VLCDR1
QDINSY
VLF2
LSWFQQKPGKSPKTLMY
VLCDR2
RAN
VLF3
RLVDGVPSRFSGSGSGQDYSLTISSLEYEDMGIYYC
VLCDR3
LQYDEFPPT
VLF4
FGGGTKVEIK。
CN202010484563.8A 2020-06-01 2020-06-01 Monoclonal antibody of mouse anti-cell surface glycoprotein CD138 capable of being applied to tumor cell capture Active CN112279917B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010484563.8A CN112279917B (en) 2020-06-01 2020-06-01 Monoclonal antibody of mouse anti-cell surface glycoprotein CD138 capable of being applied to tumor cell capture

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010484563.8A CN112279917B (en) 2020-06-01 2020-06-01 Monoclonal antibody of mouse anti-cell surface glycoprotein CD138 capable of being applied to tumor cell capture

Publications (2)

Publication Number Publication Date
CN112279917A CN112279917A (en) 2021-01-29
CN112279917B true CN112279917B (en) 2024-01-05

Family

ID=74421054

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010484563.8A Active CN112279917B (en) 2020-06-01 2020-06-01 Monoclonal antibody of mouse anti-cell surface glycoprotein CD138 capable of being applied to tumor cell capture

Country Status (1)

Country Link
CN (1) CN112279917B (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2198884A1 (en) * 2008-12-18 2010-06-23 Centre National de la Recherche Scientifique (CNRS) Monoclonal antibodies directed against LG4-5 domain of alpha3 chain of human laminin-5
CN103103197A (en) * 2013-01-30 2013-05-15 百奇生物科技（苏州）有限公司 CD138-resistant monoclonal antibody variable region sequence as well as preparation method and application thereof
CN107383199A (en) * 2017-03-15 2017-11-24 艾比玛特医药科技（上海）有限公司 A kind of monoclonal antibody of S adenomethionine synthases and its application

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ596807A (en) * 2009-05-06 2013-09-27 Biotest Ag Uses of immunoconjugates targeting cd138
TWI588259B (en) * 2015-03-06 2017-06-21 Methods for screening antigen-specific fusion tumor cells
RU2611685C2 (en) * 2015-07-20 2017-02-28 Илья Владимирович Духовлинов Humanized monoclonal antibody specific to syndecan-1

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2198884A1 (en) * 2008-12-18 2010-06-23 Centre National de la Recherche Scientifique (CNRS) Monoclonal antibodies directed against LG4-5 domain of alpha3 chain of human laminin-5
CN103103197A (en) * 2013-01-30 2013-05-15 百奇生物科技（苏州）有限公司 CD138-resistant monoclonal antibody variable region sequence as well as preparation method and application thereof
CN104059151A (en) * 2013-01-30 2014-09-24 百奇生物科技（苏州）有限公司 Anti-CD138 monoclonal antibody variable region sequence and preparation method thereof
CN107383199A (en) * 2017-03-15 2017-11-24 艾比玛特医药科技（上海）有限公司 A kind of monoclonal antibody of S adenomethionine synthases and its application

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CD138-directed adoptive immunotherapy of chimeric antigen receptor (CAR)-modified T cells for multiple myeloma;Guo等;Journal of Cellular Immunotherapy;第02卷(第01期);28-35 *
抗人CD138单克隆抗体以及重组双特异性抗体的开发及应用;陈丹等;免疫学杂志;第31卷(第01期);7-11 *
鼠抗人Syndecan-1分子功能性单克隆抗体的制备及其生物学特性;孙万平等;现代免疫学;第26卷(第05期);387-390 *

Also Published As

Publication number Publication date
CN112279917A (en) 2021-01-29

Similar Documents

Publication Publication Date Title
JP4964957B2 (en) Anti-drug antibody assay
CN112094346B (en) Monoclonal antibody of mouse anti-cell single-chain transmembrane glycoprotein CD142 capable of being applied to tumor cell capture
CN103483450A (en) Immunoassay method for human cxcl1 protein
CN115819585A (en) anti-LAG-3 monoclonal antibody, antigen binding fragment thereof and application thereof
CN108276492A (en) Anti- PD-L1 monoclonal antibodies and its application
CN106866820B (en) Monoclonal antibody for capturing tumor cells and resisting human keratin 18 and application thereof
CN117720650B (en) Anti-human respiratory syncytial virus antibody and application thereof
CN116199772A (en) HPV31 type capsid protein L1 monoclonal antibody, preparation method and application
CN112279917B (en) Monoclonal antibody of mouse anti-cell surface glycoprotein CD138 capable of being applied to tumor cell capture
Charlermroj et al. Comparison of techniques to screen and characterize bacteria-specific hybridomas for high-quality monoclonal antibodies selection
CN115724983B (en) Anti-idiotype antibody for anti-CSF 1R monoclonal antibody and application thereof
CN115286715B (en) anti-CD3 nano antibody or antigen binding portion thereof and preparation method thereof
EP3656794A1 (en) Composition and methods for detecting cancer
CN116375867A (en) anti-GPRC 5D antibody and application thereof
CN115925909A (en) Anti-respiratory syncytial virus antibodies and uses related thereto
CN110850067A (en) Chimeric antigen receptor affinity detection method
CN112094350B (en) Monoclonal antibody of mouse anti-cell surface glycoprotein CD326 applicable to tumor cell capture
CN112094345B (en) Mouse anti-immunoglobulin associated beta CD79b monoclonal antibody applicable to tumor cell capture
TW202210525A (en) Rabbit antibodies to human immunoglobulins g
JP5770092B2 (en) Monoclonal antibody against human HIG1 polypeptide
CN117683121B (en) Anti-varicella-zoster virus antibodies and uses thereof
CN117304327B (en) Anti-goat IgG rabbit monoclonal antibody and application thereof
JP5448424B2 (en) Reagent for measuring protein containing Fc of human IgG
WO2023109785A1 (en) Antibody and kit for detecting stnfr2 in serum
KR102557149B1 (en) Monoclonal Antibodies for detecting the structural protein antibodies against Foot and Mouth Disease Virus serotype A and using the same

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant